Kalman LLC

Vulcan Biologics, Inc is a cutting-edge biotechnology company based in Irvine, CA that specializes in next-generation microbiome modulation. With a focus on integrative and advanced approaches, they aim to achieve predictable stability in engineered microbiomes, offering a promising solution to the challenges faced by current reductionist methods. Their innovative technology platform holds great potential for commercial and clinical success in the field of microbiome research. As experts in the field, Vulcan Biologics recognizes the vast opportunity presented by the microbiome, which impacts the health and sustainability of all living organisms. By harnessing the power of microbiome modulation, they strive to unlock the keys to long-term survival and contribute to advancements in various sectors, including human health, animal welfare, plant cultivation, and aquatic ecosystems.Generated from the website

Neuraegis, Inc. is a preclinical-stage neuropharmaceutical company based in Irvine, California, focused on pioneering the development of novel protease inhibitors for the treatment of neurological disorders, including traumatic brain injury (TBI), concussion, and epilepsy. With an initial emphasis on TBI, where there are currently no FDA-approved treatments, the company aims to address significant unmet medical needs in this area. Recognizing TBI as a major public health issue, Neuraegis is committed to advancing first-in-class compounds that target neuronal damage and death following injury. The company has garnered attention for its strong intellectual property portfolio and experienced leadership team, as well as receiving substantial grants from the Department of Defense to support its research initiatives. Generated from the website

Ajk Biopharmaceutical LLC, founded in 2018 and based in Irvine, California, is a biotech research company dedicated to developing innovative transfecting agents that enhance the delivery of small interfering RNA (siRNA) into living cells. The company focuses on creating a novel cyclic peptide platform technology aimed at providing cost-effective solutions for therapeutic delivery challenges faced by pharmaceutical companies. Partum Biopharma's mission is to leverage its expertise in peptide chemistry to significantly improve siRNA delivery, demonstrating in vivo transformation of siRNA within cells. Through strategic partnerships and collaborations, the company aims to facilitate effective transfection methods across diverse cell lines while ensuring cell viability. Generated from the website